United States
Home
P&G Network Search
Pharmaceuticals:
US Products
Consumers:
Health Care Professionals:
FDA APPROVES NEW ONCE-A-MONTH DOSE OF ACTONEL FOR POSTMENOPAUSAL OSTEOPOROSIS
CINCINNATI, Bridgewater, NJ, April 24, 2008 — The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of ActonelŽ (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
More:

Prescription drugs


About P&GP

Current Drug Portfolio




For more information on these drugs, including indications and important safety information, please see the Product section of this site.

ACTONEL® (risedronate sodium tablets)

Consumer Product Information

ASACOL® (mesalamine) Delayed-Release Tablets

Consumer Product Information

DANTRIUM® (dantrolene sodium) Capsules

Product Information

DANTRIUM® Intravenous (dantrolene sodium for injection)

Product Information

DIDRONEL® (etidronate disodium) Tablets

Product Information

ENABLEX® (darifenacin) Extended Release Tablets

Product Information

MACROBID® (nitrofurantoin monohydrate/macrocrystals) Capsules

Product Information

MACRODANTIN® (nitrofurantoin macrocrystals) Capsules

Product Information




Explore About P&G Pharmaceuticals:

Who We Are  

What We Do  

Our History  

Current Alliances  

Products  








Touching lives, improving life. P&G


©2008 Procter & Gamble. All claims valid only in the U.S.  Legal Information  Privacy Statement  P&G Links

BBBOnLine Reliability Seal